Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.

MLA

Nagata, Yujiro, et al. “Immunohistochemical Expression of P53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.” International Journal of Molecular Sciences, vol. 25, no. 19, Oct. 2024, p. 10348. EBSCOhost, https://doi.org/10.3390/ijms251910348.

APA

Nagata, Y., Minato, A., Aono, H., Kimuro, R., Higashijima, K., Tomisaki, I., Harada, K., Miyamoto, H., & Fujimoto, N. (2024). Immunohistochemical Expression of p53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma. International Journal of Molecular Sciences, 25(19), 10348. https://doi.org/10.3390/ijms251910348

Chicago

Nagata, Yujiro, Akinori Minato, Hisami Aono, Rieko Kimuro, Katsuyoshi Higashijima, Ikko Tomisaki, Kenichi Harada, Hiroshi Miyamoto, and Naohiro Fujimoto. 2024. “Immunohistochemical Expression of P53 and FGFR3 Predicts Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma.” International Journal of Molecular Sciences 25 (19): 10348. doi:10.3390/ijms251910348.